| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Linda A Parker, Raphael Mechoulam, Coralynne Schliever. Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. Neuroreport. vol 13. issue 5. 2002-06-24. PMID:11973447. |
here we report that cannabidiol, a major non-psychoactive cannabinoid found in marijuana and its synthetic dimethylheptyl homolog interfere with nausea elicited by lithium chloride and with conditioned nausea elicited by a flavor paired with lithium chloride. |
2002-06-24 |
2023-08-12 |
rat |
| L Nong, C Newton, H Friedman, T W Klei. CB1 and CB2 receptor mRNA expression in human peripheral blood mononuclear cells (PBMC) from various donor types. Advances in experimental medicine and biology. vol 493. 2002-05-20. PMID:11727770. |
marijuana cannabinoid receptors (cbr), cb1 and cb2, are g protein-coupled receptors reported to be expressed in brain as well as cells of the periphery. |
2002-05-20 |
2023-08-12 |
human |
| Jenny L Wiley, Irina D Beletskaya, Edward W Ng, Zongmin Dai, Peter J Crocker, Anu Mahadevan, Raj K Razdan, Billy R Marti. Resorcinol derivatives: a novel template for the development of cannabinoid CB(1)/CB(2) and CB(2)-selective agonists. The Journal of pharmacology and experimental therapeutics. vol 301. issue 2. 2002-05-13. PMID:11961073. |
the role of the oxygen of the benzopyran substituent of delta(9)-tetrahydrocannabinol in defining affinity for brain cannabinoid (cb(1)) receptors is not well understood; however, it is known that opening the pyran ring can result in either increased potency and affinity, as in cp 55,940 [(-)-cis-3-[2-hydroxy-4(1,1- dimethyl-heptyl)phenyl]-trans-4-(3-hydroxy-propyl)cyclohexanol], or in an inactive cannabinoid, as in cannabidiol. |
2002-05-13 |
2023-08-12 |
Not clear |
| Mareshige Kojoma, Osamu Iida, Yukiko Makino, Setsuko Sekita, Motoyoshi Satak. DNA fingerprinting of Cannabis sativa using inter-simple sequence repeat (ISSR) amplification. Planta medica. vol 68. issue 1. 2002-05-08. PMID:11842329. |
chemical analysis of cannabinoid, and inter-simple sequence repeat (issr) fingerprinting of dna were used to identify different samples of cannabis sativa l. for forensic purposes. |
2002-05-08 |
2023-08-12 |
Not clear |
| R Mechoulam, L Han. The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. Pain research & management. vol 6. issue 2. 2002-05-01. PMID:11854768. |
recent advances in the understanding of the molecular basis of cannabis action are explained, including the identification of the cannabinoid receptors cb(1) and cb(2), as well as the isolation of endogenous cannabinoids from the brain and periphery. |
2002-05-01 |
2023-08-12 |
Not clear |
| H Kalan. Medicinal use of cannabis: history and current status. Pain research & management. vol 6. issue 2. 2002-05-01. PMID:11854770. |
to provide an overview of the history and pharmacology of cannabis in relation to current scientific knowledge concerning actual and potential therapeutic uses of cannabis preparations and pure cannabinoids. |
2002-05-01 |
2023-08-12 |
Not clear |
| M J Wallace, J L Wiley, B R Martin, R J DeLorenz. Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. European journal of pharmacology. vol 428. issue 1. 2002-04-02. PMID:11779037. |
cannabinoid compounds like delta9-tetrahydrocannabinol and cannabidiol have been shown to be anticonvulsant in maximal electroshock, a model of partial seizure with secondary generalization. |
2002-04-02 |
2023-08-12 |
Not clear |
| M J Wallace, J L Wiley, B R Martin, R J DeLorenz. Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. European journal of pharmacology. vol 428. issue 1. 2002-04-02. PMID:11779037. |
we first show that the cannabinoid compounds delta9-tetrahydrocannabinol (ed50 = 42 mg/kg), cannabidiol (ed50 = 80 mg/kg), and win 55,212-2 (ed50 = 47 mg/kg) are anticonvulsant in maximal electroshock. |
2002-04-02 |
2023-08-12 |
Not clear |
| M J Wallace, J L Wiley, B R Martin, R J DeLorenz. Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. European journal of pharmacology. vol 428. issue 1. 2002-04-02. PMID:11779037. |
we further establish, using the cannabinoid cb1 receptor specific antagonist n-(piperidin-1-yl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1h-pyrazole-3-carboxamidehydrochloride (sr141716a) (ad50 = 2.5 mg/kg), that the anticonvulsant effects of delta9-tetrahydrocannabinol and win 55,212-2 are cannabinoid cb1 receptor-mediated while the anticonvulsant activity of cannabidiol is not. |
2002-04-02 |
2023-08-12 |
Not clear |
| R I Wilson, R A Nicol. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature. vol 410. issue 6828. 2002-03-21. PMID:11279497. |
marijuana affects brain function primarily by activating the g-protein-coupled cannabinoid receptor-1 (cb1), which is expressed throughout the brain at high levels. |
2002-03-21 |
2023-08-12 |
Not clear |
| S A Varvel, R J Hamm, B R Martin, A H Lichtma. Differential effects of delta 9-THC on spatial reference and working memory in mice. Psychopharmacology. vol 157. issue 2. 2002-02-26. PMID:11594438. |
marijuana remains the most widely used illicit drug in the u.s., and recent attention has been given to putative therapeutic uses of marijuana and cannabinoid derivatives. |
2002-02-26 |
2023-08-12 |
mouse |
| Nissar A Darman. The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by delta(9)-tetrahydrocannabinol and other cannnabinoids. The Journal of pharmacology and experimental therapeutics. vol 300. issue 1. 2002-01-24. PMID:11752094. |
the nonpsychoactive cannabinoid, cannabidiol, was inactive. |
2002-01-24 |
2023-08-12 |
Not clear |
| S S Cui, R C Bowen, G B Gu, D K Hannesson, P H Yu, X Zhan. Prevention of cannabinoid withdrawal syndrome by lithium: involvement of oxytocinergic neuronal activation. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 21. issue 24. 2002-01-23. PMID:11739594. |
cannabis (i.e., marijuana and cannabinoids) is the most commonly used illicit drug in developed countries, and the lifetime prevalence of marijuana dependence is the highest of all illicit drugs in the united states. |
2002-01-23 |
2023-08-12 |
rat |
| S S Cui, R C Bowen, G B Gu, D K Hannesson, P H Yu, X Zhan. Prevention of cannabinoid withdrawal syndrome by lithium: involvement of oxytocinergic neuronal activation. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 21. issue 24. 2002-01-23. PMID:11739594. |
these results demonstrate that oxytocinergic neuronal activation plays a critical role in the action of lithium against the cannabinoid withdrawal syndrome in rats, thus providing a potentially novel strategy for the treatment of cannabis dependence in humans. |
2002-01-23 |
2023-08-12 |
rat |
| G Skopp, L Pötsc. [Passive exposure in detection of low blood and urine cannabinoid concentrations]. Archiv fur Kriminologie. vol 207. issue 5-6. 2002-01-03. PMID:11508050. |
the pharmacokinetics of smoked marijuana as well as experimental data on cannabinoid concentrations in plasma and urine samples following passive exposure are summarized. |
2002-01-03 |
2023-08-12 |
Not clear |
| E Gordon, O Devinsk. Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia. vol 42. issue 10. 2001-12-28. PMID:11737161. |
some evidence suggests that marijuana and its active cannabinoids have antiepileptic effects, but these may be specific to partial or tonic-clonic seizures. |
2001-12-28 |
2023-08-12 |
human |
| M D Van Sickle, L D Oland, W Ho, C J Hillard, K Mackie, J S Davison, K A Sharke. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology. vol 121. issue 4. 2001-12-05. PMID:11606489. |
marijuana and other cannabinoids are effective anti-emetics. |
2001-12-05 |
2023-08-12 |
Not clear |
| S J Tsai, Y C Wang, C J Hon. Association study between cannabinoid receptor gene (CNR1) and pathogenesis and psychotic symptoms of mood disorders. American journal of medical genetics. vol 105. issue 3. 2001-12-04. PMID:11353438. |
in brain, the main active ingredient of cannabis acts via the cannabinoid cb1 receptor (cnr1) which is located on chromosome 6q14-15. |
2001-12-04 |
2023-08-12 |
Not clear |
| L Fattore, G Cossu, C M Martellotta, W Fratt. Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats. Psychopharmacology. vol 156. issue 4. 2001-12-04. PMID:11498718. |
delta9-tetrahydrocannabinol (delta9-thc), the main psychoactive ingredient of marijuana, as well as synthetic cannabinoid (cb1) receptor agonists, has led to negative or equivocal results when tested with the intravenous self-administration procedure, the best validated behavioural model for evaluating abuse liability of drugs in experimental animals. |
2001-12-04 |
2023-08-12 |
mouse |
| A Ménétrey, M Augsburger, C Giroud, P Mangi. [Cannabis and automobile driving]. Praxis. vol 90. issue 34. 2001-12-04. PMID:11552320. |
in forensic practice, cannabis impairment of driving performance must be related to cannabinoids blood concentrations. |
2001-12-04 |
2023-08-12 |
Not clear |